Skip to main content
Premium Trial:

Request an Annual Quote

Padma Sundar, Kim Dickinson

OncoCyte has appointed Padma Sundar as its senior VP of marketing and market access. The firm has also appointed Kim Dickinson as its VP of clinical operations.

Prior to OncoCyte, Sundar served as VP of strategy and market access at CellMax Life. Before CellMax, she acted as director of marketing at Guardant Health. Prior to Guardant, Sundar served as senior director at Roche Sequencing. She also held the role of senior director for Affymetrix's oncology portfolio.

Before OncoCyte, Dickinson served as VP of research and development and chief pathologist at Biocare Medical. Prior to BioCare, she served as VP of clinical operations at Roche Tissue Diagnostics. She also served as medical director for Laboratory Corporation of America' clinical trials division. Before working at LabCorp, Dickinson acted as medical director at Esoteric Testing. Prior to Esoteric, Dickinson worked at Quest Diagnostics, Citrus Valley Medical Center, and Pioneer Hospital.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.